FDA Warns of Kaletra Toxicity for Premature Infants
3-11-2011

Analysis of clinical outcomes in African American HIV-1 positive patients receiving lopinavir/ritonavir in a large urban AIDS clinic
8-17-2010

Clinical outcomes, immmunologic function and virologic suppression among HIV infected children receiving Lopinavir/ritonavir-based second line antiretroviral therapy at National Pediatric Hospital, Phnom Penh, Cambodia
8-17-2010

Comparison of total and unbound lopinavir (LPV) pharmacokinetics (PK) in HIV-infected pregnant women receiving lopinavir/ritonavir (LPV/r) soft-gel capsules (SGC) or tablets
8-17-2010

Antiretroviral monotherapy with ritonavir-boosted lopinavir or fosamprenavir in HIV-cirrhotic patients is a safe, effective and costs-saving strategy
8-17-2010

Lopinavir/ritonavir combined with raltegravir demonstrated similar antiviral efficacy and safety as lopinavir/ritonavir combined with tenofovir disoproxil fumarate/emtricitabine in treatment-naïve HIV-1 infected subjects
8-17-2010

Baseline HIV-1 RNA does not affect virologic response to lopinavir/ritonavir-based regimens in antiretroviral-naive subjects: results of a 96-week meta-analysis of >2400 subjects
8-17-2010

Market shift towards heat-stable lopinavir/ritonavir demonstrates the need for improved formulations for second line treatment of HIV/AIDS in low- and middle-income countries
8-17-2010

The effect of lopinavir/r monotherapy on viral load and on the selection of resistance-associated mutations in seminal plasma
8-17-2010

Incidence of emtricitabine, tenofovir, raltegravir, and lopinavir resistance following twice-daily (BID) lopinavir/ritonavir (LPV/r) in combination with once-daily (QD) emtricitabine/tenofovir (FTC/TDF) or twice daily raltegravir (RAL) in antiretroviral-naïve, HIV-1 infected subjects: 48-week results of a 96-week randomized trial (study M10-336)
8-17-2010

The effect of lopinavir/ritonavir on the pharmacokinetics of TMC207, an investigational antimycobacterial agent
8-17-2010

Real-life safety and efficacy of lopinavir/ritonavir (LPV/r) in drug-naive and antiretroviral (ARV) treatment-experienced HIV patients: 96-week follow-up
8-17-2010

NRTI-sparing Regimen of Lopinavir/ritonavir plus Raltegravir Works as Well as Traditional 3-drug HAART
7-23-2010

Switching from Kivexa [ABC/3TC ]+Kaletra [LPV/r] to Truvada [TDF/FTC]+Kaletra [LPV/r] Reduces High Cholesterol: Results of a 12 Week Randomized, Controlled Study (ROCKET II)
7-23-2010

NRTI-sparing Regimen of Lopinavir/ritonavir plus Raltegravir Works as Well as Traditional 3-drug HAART
7-23-2010

Suboptimal Adherence Has Less Effect on Boosted Darunavir (Prezista) than Lopinavir/ritonavir (Kaletra)
7-02-2010

FDA Approves Once-daily Lopinavir/ritonavir (Kaletra) for Certain Treatment-experienced HIV Patients
4-30-2010

FDA Announces Label Changes for Darunavir (Prezista), Didanosine (Videx), and Lopinavir/ritonavir (Kaletra)
2-02-2010

Raltegravir (Isentress) Activity Is Durable at 96 Weeks; Switch from Lopinavir/ritonavir Results in More Viral Breakthrough but Better Lipid Profiles
1-26-2010

Tenofovir/emtricitabine (Truvada) plus Lopinavir/ritonavir (Kaletra) or Raltegravir (Isentress) Work Well for Post-exposure Prophylaxis
9-11-2009

At 96 Weeks, Epzicom and Truvada Demonstrate Comparable Efficacy, Safety, and Tolerability when Combined with Lopinavir/ritonavir (Kaletra)
8-4-2009

Once-daily Lopinavir/ritonavir (Kaletra) Works as Well as Twice-daily dosing in Treatment-naive HIV Patients
7-31-2009

Switching from Lopinavir/ritonavir (Kaletra) to Boosted Atazanavir (Reyataz) Reduces Visceral Fat and Improves Glucose Metabolism
7-10-2009

Protease Inhibitor Monotherapy using Lopinavir/ritonavir (Kaletra) or Boosted Atazanavir (Reyataz) Maintains Viral Suppression
6-19-2009

How Effective Are Boosted Dual Protease Inhibitor Regimens with No Additional Drugs in Treatment-naive HIV Patients?
5/22/09

First-line Therapy with Zidovudine/lamivudine plus Lopinavir/ritonavir Leads to Greater Bone Loss than Nevirapine plus Lopinavir/ritonavir
5/19/09

Lopinavir/ritonavir (Kaletra) Is Superior to Nevirapine (Viramune) for HIV-infected Children Who Received Single-dose Nevirapine at Birth
5/15/09

Raltegravir (Isentress) plus Lopinavir/ritonavir (Kaletra) Produces Rapid Viral Load Decline in Treatment-naive HIV Patients
5/08/09

Raltegravir (Isentress) plus Lopinavir/ritonavir (Kaletra) Produces More Rapid HIV Decline in Treatment-naive HIV Patients
4/10/09

Lopinavir/ritonavir (Kaletra) Label Changed to Reflect Potential Risk of Heart Rhythm Abnormalities
4/10/09

Lopinavir/ritonavir (Kaletra) Monotherapy May Be Hazardous for Patients with a History of Low CD4 Cell Counts
3/03/09

Switching from Lopinavir/ritonavir (Kaletra) to Raltegravir (Isentress) Leads to Poorer HIV Suppression, but Better Lipid Profiles: SWITCHMRK
2/17/09

Factors affecting virologic response to darunavir/ritonavir and lopinavir/ritonavir in treatment-naïve HIV-1-infected patients in ARTEMIS at 96 weeks
2/17/09

Single Agent Therapy with Lopinavir/Ritonavir Suppresses HIV-1 Viral Replication in ARV Naïve Patients: IMANI II - 96 Week Final Results
11/05/2008

Three-year Efficacy of Lopinavir/ritonavir Monotherapy in the OK04 Trial
11/05/2008

Time to Virological Failure with Boosted Atazanavir (Reyataz) or Lopinavir/ritonavir (Kaletra) Is Not Affected by Use of H2 Receptor Blockers
9/12/2008

Effect of Lopinavir/ritonavir (Kaletra) Monotherapy on Symptoms and Quality of Life
9/12/2008

No Increased Risk of Birth Defects with Prenatal Lopinavir/ritonavir (Kaletra) Exposure
8/22/08

Time to Virological Failure with Boosted Atazanavir (Reyataz) or Lopinavir/ritonavir (Kaletra) Is Not Affected by Use of H2 Receptor Blockers
9/12/2008

Boosted Atazanavir and Lopinavir/ritonavir (Kaletra) Have Similar Efficacy, but Side Effects Differ across Racial/ethnic Groups
8/12/08

Lopinavir/ritonavir (Kaletra) Tablet Dosed Once-Daily or Twice-Daily Confers Similar Clinical Results across Racial/ethnic Lines
8/12/08

Trough Lopinavir Concentrations <1 ƒÊg/mL Are Not Associated with Virologic Failure in Antiretroviral-Naive Patients Receiving a Lopinavir/ritonavir-Based 3-Drug Regimen
8/10/08

Impact of Gender on Response to Lopinavir/ritonavir (LPV/r) Tablets Dosed QD or BID Administered with Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine (FTC) in Antiretroviral-naïve (ARV) Subjects: Results from Study M05-730
8/10/08

Comparable HIV-1 Viral Suppression and Immunologic Recovery of White and Non-White Antiretroviral-Naïve Subjects Taking Lopinavir/ritonavir (LPV/r) Tablets + Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine (FTC) through 48 Weeks
8/10/08

Week-96 End of Trial Analysis of Antiretroviral-naïve Patients Randomized to the Lopinavir/ritonavir Single Drug Arm in the MONARK Trial
8/10/08

Predictors of Persistence with Lopinavir/ritonavir (LPV/r) Soft-Gelatin Capsule-Based Antiretroviral Regimens
8/10/08

Health-Related Quality of Life (HRQoL) Improvement in Antiretroviral (ARV) Naïve HIV-infected Patients on Atazanavir or Lopinavir With Ritonavir Regimens: Week 24 Results From the CASTLE Study
8/10/08

Efficacy and Safety By Racial Group in ARV-Naïve Subjects Treated With Atazanavir/Ritonavir or Lopinavir/Ritonavir: 48-Week Results for the CASTLE Study (AI424138)
8/10/08

Health-Related Quality of Life (HRQoL) Improvement in Antiretroviral (ARV) Naïve HIV-infected Patients on Atazanavir or Lopinavir with Ritonavir Regimens: Week 24 Results From the CASTLE Study
8/10/08

Epzicom QD vs Truvada QD, Both with Kaletra QD, in ART-Naïve Patients: The HEAT Study 96 Weeks Analysis Results
8/10/08